Brokerages Anticipate Dova Pharmaceuticals Inc (DOVA) to Post -$0.79 Earnings Per Share
Analysts predict that Dova Pharmaceuticals Inc (NASDAQ:DOVA) will report earnings of ($0.79) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Dova Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.87) and the highest is ($0.75). Dova Pharmaceuticals posted earnings per share of ($0.36) in the same quarter last year, which suggests a negative year-over-year growth rate of 119.4%. The business is expected to issue its next earnings results on Thursday, February 21st.
On average, analysts expect that Dova Pharmaceuticals will report full-year earnings of ($2.70) per share for the current year, with EPS estimates ranging from ($2.78) to ($2.65). For the next financial year, analysts forecast that the business will report earnings of ($2.50) per share, with EPS estimates ranging from ($2.90) to ($1.71). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Dova Pharmaceuticals.
A number of analysts have recently issued reports on the company. BidaskClub raised Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, December 13th. Zacks Investment Research lowered Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 30th. JPMorgan Chase & Co. lowered Dova Pharmaceuticals from an “overweight” rating to an “underweight” rating and dropped their target price for the stock from $34.00 to $20.00 in a research report on Wednesday, January 23rd. LADENBURG THALM/SH SH lifted their target price on Dova Pharmaceuticals to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 18th. They noted that the move was a valuation call. Finally, HC Wainwright began coverage on Dova Pharmaceuticals in a research report on Thursday, December 20th. They set a “buy” rating and a $18.00 target price on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. Dova Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $29.50.
In other Dova Pharmaceuticals news, CEO David Zaccardelli acquired 10,000 shares of Dova Pharmaceuticals stock in a transaction dated Thursday, December 20th. The stock was acquired at an average cost of $6.07 per share, for a total transaction of $60,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul B. Manning acquired 266,631 shares of Dova Pharmaceuticals stock in a transaction dated Thursday, December 20th. The shares were acquired at an average price of $6.17 per share, with a total value of $1,645,113.27. The disclosure for this purchase can be found here. 55.50% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of DOVA. GSA Capital Partners LLP acquired a new stake in Dova Pharmaceuticals in the third quarter worth approximately $1,292,000. Birchview Capital LP acquired a new stake in Dova Pharmaceuticals in the third quarter worth approximately $629,000. Bank of America Corp DE lifted its position in Dova Pharmaceuticals by 81.3% in the second quarter. Bank of America Corp DE now owns 5,305 shares of the company’s stock worth $159,000 after purchasing an additional 2,379 shares during the period. Raymond James & Associates acquired a new stake in Dova Pharmaceuticals in the second quarter worth approximately $1,465,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Dova Pharmaceuticals in the third quarter worth approximately $242,000. Institutional investors and hedge funds own 36.90% of the company’s stock.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Further Reading: How to interpret the current ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.